COVID-19 Impact

You may see some delays in posting new content due to COVID-19. If you have any questions, please submit a message to PSNet Support.
 

PSNet: Patient Safety Network
Web Resource
Government Resource

Relenza (zanamivir) inhalation powder.

Food and Drug Administration; FDA.

This alert notifies health care providers of the potential for patient harm if a particular inhalation powder is reconstituted and incorrectly administered.